Oncotarget

Corrections:

Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer

PDF  |  How to cite

Oncotarget. 2019; 10:685-685. https://doi.org/10.18632/oncotarget.26625

Metrics: PDF 841 views  |   ?  

Jonathan P. Evans1,*, Boleslaw K. Winiarski2,*, Paul A. Sutton1, Robert P. Jones1, Lorenzo Ressel3, Carrie A. Duckworth4, D. Mark Pritchard4, Zhi-Xiu Lin5, Vicky L. Fretwell1, Elizabeth M. Tweedle1, Eithne Costello1, Christopher E. Goldring2, Ian M. Copple2, B. Kevin Park2, Daniel H. Palmer1,6 and Neil R. Kitteringham2

1 Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
2 MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
3 Department of Veterinary Pathology, Institute of Veterinary Science, University of Liverpool, Liverpool, United Kingdom
4 Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
5 School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, People’s Republic of China
6 Clatterbridge Cancer Centre, Liverpool, United Kingdom
* Joint first authorship

Published: January 18, 2019

This article has been corrected: The correct Author name is given below:

Vicky L. Fretwell

Original article: Oncotarget. 2018; 9:27104-27116. DOI: https://doi.org/10.18632/oncotarget.25497.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26625